Authorities in US & Europe have called for new drugs to augment antibiotics, which are being overwhelmed by bacterial resistance. Staphylococcus aureus (SA) is a major cause of post-surgical infection costs the US $12 billion pa.
Destiny Pharma has developed a new class of drug with outstanding, rapid, bactericidal activity against SA. The lead drug, XF-73 has completed 3 UK clinical trials aimed at clearing SA from the nose (the major site for SA in the body). Unlike traditional antibiotics, XF-73 has demonstrated the remarkable quality of withstanding SA bacterial resistance.
The US government’s National Institute for Allergy & Infectious Disease is funding the first US clinical trial of XF-73 which is on-going.
An XF-73 product would be used to clear SA from patients ahead of surgery - reducing their risk of infection - new US guidelines are recommending more widespread clearance of SA - but SA resistance is a major concern for antibiotics - XF-73 can provide the solution